AdaptHealth price target lowered to $20 from $28 at Truist

Truist lowered the firm’s price target on AdaptHealth to $20 from $28 but keeps a Buy rating on the shares. The analyst cites the company’s "disappointing" Q4 results and FY23 guidance cut driven by cost pressure and revenue mix. AdaptHealth’s new cost containment programs are encouraging, but execution is paramount and free cash flow generation is key, Truist tells investors in a research note.